Interestingly, the E6 and E7 proteins from the low-risk HPV types also inhibited MIP-3oa transcription. These results suggest that one mechanism by which HPV-infected cells suppress the immune response may be through the inhibition of a vital alert signal, thus, contributing to the persistence of HPV infection.
controlling an HPV infection comes from the high prevalence and persistence of HPV infections in immunosuppressed individuals (63) . In general, the mucosal immune response to an infection begins with the cells of the epidermis secreting alarm signals which act on immune cells as well as the infected cells. Chemokines, cytokines, adhesion molecules and proteases direct the migration of leukocytes, monocytes, lymphocytes, neutrophils, eosinophils, basophils, natural killer cells, dendritic cells, and endothelial cells (55) , while interferons inhibit viral replication within the infected cells (64) .
Evasion of the immune response would contribute to the survival and propagation of HPV-infected cells. Two genes in the high-risk HPVs, E6 and E7, are associated with the virus's oncogenic potential to transform infected cells. In addition to their well-documented effects on cell cycle and differentiation, E6 and E7 also negatively impact the immune response by inhibiting the production of immune mediators. Expression of E6 is inversely correlated with the expression of interleukin-18 (IL-18), a pro-inflammatory cytokine similar to IL-I that induces interferon-y (IFN-y) production (10) . E6 and, to a lesser extent, E7 down-regulate the expression of IL-8, a chemoattractant for T cells (28). E6 and E7 also suppress the expression of a chemokine, monocyte chemoattractant protein-1 (MCP-1), in female genital epithelial cells (35) .
Additionally, E6 and E7 contribute to the escape from the antiviral and antiproliferative properties of tumor necrosis factor-a (TNF-a) and IFN-a through growth stimulatory effects, loss of TNF-sensitivity, and interaction with components of the IFN signaling pathway (61) . Among the chemokines and cytokines secreted by epidermal cells, macrophage inflammatory protein-3a (MIP-3a) is the most potent chemokine for LC precursors and dermal dendritic cells (12) . Originally discovered to be expressed in lung and liver tissue (56) , liver and activationinduced chemokine (LARC)/CCL20/MIP-3a is also produced in intestinal epithelium and epidermal keratinocytes (14, 26) , but primarily in areas of inflamed epithelium (9, 46) . MIP-3a expression can be increased by TNF-a, IL-1 a, or IL-103 in oral squamous cell carcinomas, intestinal epithelial cells, and keratinocytes (1, 12, 26, 32, 36, 46, 67) . Immature dendritic cells, memory T cells, and epidermal LCprecursors migrate in response to MIP-3a due to their selective expression of CC chemokine receptor 6, CCR6 (19, 37, 40, 54) .
Investigations of cervical biopsies revealed that the number of LCs was significantly reduced in intraepithelial neoplasia and low-grade/high-grade lesions when compared to normal tissue (2, 11, 70) . Thus, areas of HPV persistence exhibiting decreases in LC density suggest decreased immune surveillance. Our studies show that human keratinocytes expressing HPV-16 E6 and E7 produce less MIP-3a than control cells. The result of this lack of secreted MIP-3a is a reduction in the migration of Langerhans precursor-like cells. Our results suggest that the downregulation of MIP-3a is one mechanism by which HPV infections could evade the immune response and persist undetected in the epithelium.
Materials and Methods

Keratinocyte culture and preparation of cell lines
Primary human foreskin keratinocytes (HFKs) were isolated from neonatal foreskins and cultured in EpiLife medium supplemented with human keratinocyte growth supplement (bovine pituitary extract, bovine insulin, hydrocortisone, bovine transferrin, human epidermal growth factor) and penicillin/streptomycin/amphotericin B (PSA) solution (Cascade Biologics). Cells were cultured in EpiLife medium supplemented without bovine pituitary extract and hydrocortisone (hereafter called minimal EpiLife) when culture supernatants were harvested for use in ELISAs and migration assays.
Generation of stable cell lines expressing HPV-16 E6/E7, HPV-6 E6/E7, and HPV-11 E6/E7 was accomplished using the pBabe retroviral system (43) . Retrovirus encoding either vector alone or E6/E7 from HPV-16, HPV-6, and HPV-11 was produced by transfecting DNX packaging cells (American Type Culture Collection) with vesicular stomatitis virus envelope gene and pBabe retroviral constructs by calcium phosphate method (BD Biosciences), according to the manufacturer's protocol. 48 h after transfection, retrovirus was concentrated by centrifugation for 90 min at 15,000 rpm, 4°C, and virus pellets were resuspended in 2mL EpiLife overnight at 4°C. Resuspended virus was either used immediately to infect HFKs or frozen at -80'C for future use. Resuspended virus was used to infect HFKs in 8gg polybrene per mL of EpiLife for 5 h. Cells were allowed to recover for 24 h and then selected with 1.25jig/mL puromycin for 2-4 days. Stable cell lines were expanded for treatment with polyinosinepolycytidylic acid [Poly(I)-Poly(C)] (Amersham Biosciences).
Generation of E6 and E7mutations
Mutagenesis of E6/E7 was performed on HPV-16 E6/E7 in pGEM7Zf using the QuikChange kit (Stratagene). The following primers were used to generate a stop codon at 16 49) , were generated in combination with E7stop and E6stop respectively. The primers listed previously were used to mutate HPV-16 E6(C66G/C 136G)/E7 in pGEM7ZF to generate E6(C66G/C136G)/E7stop. Mutagenesis of E7 was performed on HPV-16 E6stop/E7 in pGEM7Zf using the QuikChange kit (Stratagene). The following primers were used to generate an amino acid substitution of histidine to proline at position 2 (forward GCTGTAATCATGCCTGGAGATACACCTACA; reverse TGTAGGTGTATCTCCAGGCATGATTACAGC). The mutants were sequenced and subcloned into the pBabe retroviral vector.
Measurement of MIP-3a by qPCR and ELISA
1 x 106 cells were seeded on 10-cm dishes 24 h prior to treatment with Poly(I).Poly(C).
Cells were treated with 100jtg/mL Poly(I).Poly(C) in antibiotic-free EpiLife for 16 h, washed 5 times with PBS, and refed with minimal EpiLife for 4 h. Cells were harvested for RNA isolation, and culture supernatants were collected for use in ELISAs and migration assays. 
Migration assay
Migration assays were carried out using 24-well Transwell plates with 5-Rtm pore size polycarbonate filters (Costar 3421). Briefly, 2 x 10 5 LPLCs in 100[tL medium were added to the upper wells and 600 tL of conditioned medium was added to the lower wells. Cells were allowed to migrate for 4 h at 37°C under 5% CO 2 . Migrated cells and medium from the lower wells were collected, spun down for 5 min at 1200rpm, 4VC, resuspended in medium and counted using a hemacytometer. The number of cells that migrated in response to unconditioned medium was subtracted from the number of cells migrating in response to conditioned medium to control for nonspecific migration. Recombinant human MIP-3a (Peprotech) and anti-human MIP-3a antibody (R & D Systems) were used in the compensation and neutralization migration assays. Each sample was run in duplicate in each experiment and paired t-test was used to generate p values.
Reporter assay
HFKs were seeded in 6-well dishes at a density of 1 x 10 5 cells per well. The luciferase reporter construct, kindly provided by Andrew Keates, consisted of an 849-bp fragment of the MIP-3a promoter cloned into the pGL3-Basic firefly luciferase expression vector (MIP-3aWT).
A mutant reporter construct was also used which contained 4 nucleotide substitutions in the NF-KB binding element on the promoter (MIP-3amNFKB). Cells were transfected 24 h later with 100ng MIP-3aWT or MIP-3amNFKB and 900ng pSG5 using Fugene 6 (Roche). 24 h after transfection, cells were washed with lx PBS, refed with PSA-free EpiLife, and left untreated or treated with 10•tg/mL Poly(I).Poly(C), 1Ong/mL TNF-a, or 1Ong/mL IL-1I3 for 6 h. Following treatment, cells were harvested, lysed, and measured for luciferase activity as described previously (42, 49) . Assays were carried out in triplicate for each sample.
Micro fluidic card analysis
As described previously, 1 x 106 cells were seeded on 10-cm dishes 24 h prior to treatment with Poly(I).Poly(C). Following treatment and addition of minimal EpiLife, cells were harvested and total RNA was extracted using the RNeasy mini kit (Qiagen), according to the manufacturer's instructions. RNA was provided to the University of Rochester Functional Genomics Center for cDNA amplification and RT-PCR gene expression quantification using micro fluidic cards (Applied Biosystems) containing primers specific for a panel of genes implicated in the immune response. Following sample loading, cards were run on the ABI PRISM 7900HT Sequence Detection System (Applied Biosystems) and data was analyzed using the Sequence Detection System (SDS) 2.2 software using GAPDH as the endogenous control and the control cell line (Babe) set as the calibrator sample (expression equal to 1). Each sample was run in quadruplicate in each experiment and paired t-test was used to generate p values.
Results are expressed as the average fold reduction in gene expression for three experiments using three independent cell lines. Paired t test was used to generate p values. Only those targets where fold reduction was statistically significant (p<0.05) are listed in Table 1 .
Results MIP-3a mRNA and protein is decreased in HPV-16 E6/E7-expressing keratinocytes. From microarray analysis performed in order to identify genes differentially regulated in E6/E7-expressing HFKs compared to control cells (50) , several genes involved with immune regulation (IL-la, IL-8, MIP-3a, TNF-a) were identified as being down-regulated in the E6/E7-expressing cells. To obtain a more accurate picture of immune response genes that are de-regulated by E6/E7, microfluidic cards of 96 immune-related genes were used for real-time PCR quantitation.
HFKs were stably infected with retrovirus carrying either vector alone (Babe) or a vector containing HPV-16 E6 and E7 in tandem (E6/E7). In order to stimulate cytokine/chemokine production, keratinocytes were activated with Poly(I).Poly(C), which has been shown to efficiently activate keratinocytes (38) Detection System (SDS) and data was analyzed with SDS 2.2 software using GAPDH as the endogenous control. Results from the micro fluidic cards validated the immune genes known to be down-regulated in E6/E7-expressing keratinocytes from the microarray and also identified additional cytokines, chemokines, receptors, and wound healing factors that were downregulated in Poly(I).Poly(C)-stimulated E6/E7-expressing keratinocytes ( Table 1) .
Many of these genes may not be direct targets of E6/E7. For instance, the expression of RANTES, enthothelin 1 (EDN 1), and complement component 3 (C3) in keratinocytes is increased after stimulation with TNF-a (39, 48, 68) . IL-1l3 induces the production of TNF-a, and IL-15 stimulates inducible nitric oxide synthetase (iNos) in keratinocytes (23, 73) . It is possible that down-regulation of these genes may be an indirect result of repression of TNF-a, IL-1I3, and IL-15 by E6/E7. MIP-3a expression has been shown to up-regulated by TNF-a, IL-la, and IL-1J3 (12, 26, 36, 46, 67) . Initial experiments using a MIP-3a promoter assay in primary human keratinocytes demonstrated that E6 and E7, both in cooperation and individually, can repress MIP-3ca promoter activity even in the presence of exogenously added IL-1 3 (data not shown).
These results suggested that expression of E6/E7 was having a direct effect on MIP-3a transcription. Since MIP-3a was not provided as a target gene on the micro fluidic card, it was necessary to perform separate real-time PCR to validate the repression of MIP-3a observed in the microarray. Additionally, MIP-3a was selected for further investigation due to its selective and potent role in the recruitment of LCs during the innate immune response.
To examine the effect of E6/E7 on MIP-3a mRNA and protein levels, control and E6/E7-expressing cells were stimulated with Poly(I).Poly(C) for 16 h. After six days in culture, LPLCs were used in Transwell cell culture chambers to determine their migratory response to culture supernatants from Poly(I).Poly(C)-treated control and E6/E7-expressing keratinocytes. The migratory response of the LPLCs to MIP-3a was first tested to confirm that the level of CCR6 expression generated under the culture conditions described in this study would allow investigation of differences in migration between supernatants from control and E6/E7-expressing keratinocytes. In three independent experiments, the addition of 1OOng/mL MIP-3a to minimal media increased migration of LPLCs an average of 2.5-fold (data not shown). The migration of three independent LPLC cultures was then tested against matched supernatant from three independent cell lines of E6/E7-expressing keratinocytes and each migration assay involved duplicates of every test sample. As shown in Figure 2B , exposure to supernatant from E6iE7-expressing keratinocytes resulted in a 1.5-fold reduction in the number of migrating LPLCs (p<0.001).
Decreased migration of LPLCs is specific to the reduction of MIP-3a by HPV-16 E6/E7-expressing keratinocytes. To determine the role of MIP-3a in the migratory response of LPLCs, MIP-3a was added to conditioned media from E6/E7-expressing keratinocytes. The amount of exogenous MIP-3a added to each migration assay was calculated from ELISAs carried out on the culture supernatants from Poly(I).Poly(C)-treated control and E6/E7-expressing keratinocytes ( Figure 1B) . The number of migrating LPLCs increased, following addition of exogenous MIP-3a to supernatant from E6/E7-expressing keratinocytes, to the level of LPLCs migrating in response to supematant from control cells ( Figure 3A ). To further examine the effect of MIP-3a on migrating LPLCs, neutralizing antibody to MIP-3a was added to supernatant from Poly(I).Poly(C)-treated control cells. Similar to the compensation assays, the amount of MIP-3a to be neutralized in the migration assay was calculated from ELISAs carried out on culture supernatants ( Figure 11B ). The approximate amount of neutralizing antibody to be used was calculated using the Neutralization Dose 5 0 provided on the technical data sheet. Use of the neutralizing antibody resulted in a reduction in the migration of LPLCs to the level of that seen with supernatant from E6/E7-expressing keratinocytes ( Figure 3B ).
Both E6 and E7 decrease MIP-3a mRNA and protein levels in keratinocytes. In order to investigate the individual contributions of E6 or E7 to the repression of MIP-3a, cell lines that expressed each oncoprotein were generated. Retroviral constructs containing stop codons in either E6 or E7 of HPV-16 were used to produce keratinocytes expressing considerable levels of E6 alone (E6/E7stop) and E7 alone (E6stop/E7). To determine the effects of E6 or E7 on the down-regulation of MIP-3a, control, E6/E7, E6, and E7-expressing cells were stimulated with Poly(I).Poly(C) as described previously. Following treatment, cells were harvested for evaluation by real-time qPCR, and culture supernatants were collected for use in ELISA analysis. The results following treatment of three independent cell lines showed that E6/E7-expressing keratinocytes had the greatest repression (75%) in MIP-3a mRNA levels compared to control cells, followed by E6-expressing cells (62%) and E7-expressing cells (58%) ( Figure 4A ).
Similar to the data shown in Figure 1 , the levels of secreted MIP-3a protein parallel the mRNA levels, with E6/E7-expressing keratinocytes secreting the least amount of MIP-3a (84pg/mL) compared to control cells (304pg/mL), followed by E6-expressing cells (88pg/mL) and E7-expressing cells (178pg/mL) ( Figure 4B ).
Decreased MIP-3a expression also occurs in low-risk HPV types. Although not prone to oncogenic transformation of the cells they infect, the capacity for low-risk HPVs to evade the host immune response would be beneficial to the persistence and propagation of the virus. To examine whether suppression of MIP-3a is unique to only the high-risk HPV types, cell lines were generated carrying HPV-16 E6/E7, HPV-6 E6/E7, or HPV-11 E6/E7. The cell lines and control keratinocytes were treated with Poly(I).Poly(C) as before, then cells and culture supernatants were harvested for qPCR and ELISA analysis. Real-time PCR and ELISA results revealed similar reductions in MIP-3a mRNA levels among all three HPV types, as well as decreased production of MIP-3a protein when compared to control cells ( Figures 5A and 5B) .
Results showing MIP-3a suppression in cells expressing E6 or E7 individually (Figures 4A and 4B) suggest that both E6 and E7 contribute to the repression of MIP-3a; however, the mechanism underlying this inhibition is not known. For high-risk HPVs, their oncogenic potential has often been linked to the ability of E6 to bind and degrade p53 and of E7 to bind to retinoblastoma (Rb) and abrogate the functions of the Rb family members (27, 30, 51, 59).
Therefore, one possible mechanism of the effect of HPV-16 E6 and E7 on MIP-3a expression would be through their interactions with p53 and Rb. However, E6 of HPV-6 and HPV-11 shows no binding to or degradation of p53 (58, 72) , and E7 of HPV-6 and HPV-1 1, while binding to Rb, do so to a lesser extent than that seen with E7 of high-risk HPVs (24, 45). The ability of E6/E7 from high-risk and low-risk HPV types to repress MIP-3a transcription suggests that the inhibition of MIP-3a is through a mechanism independent of the effects of E6 and E7 on p53 and Rb. NF-KB is required for MIP-3a expression in keratinocytes. The pro-inflammatory cytokines TNF-a and IL-I 3 have been shown to induce MIP-3a through NF-icB activation (14, 22, 31, 36, 65) . To determine if MIP-3a expression in human keratinocytes requires NF-iJB, reporter assays were performed using luciferase constructs containing either the full-length MIP-3a promoter or the full-length MIP-3a promoter containing a substitution mutation in the NF-KB binding site. Figures 6A and 6B , the mutated NF-KB binding site decreased basal MIP-3a activity as well as induction by Poly(I).Poly(C), TNF-a, and IL-1 I3.
As shown in
The central role of NF-iB in mediating the immune response has been clarified through the investigation of NF-iB activity in response to bacterial and viral infections as well as the regulation of numerous cytokines, chemokines, receptors, wound healing factors, and cell adhesion molecules by NF-KB (17, 47, 57) . Activation of transcription by NF-KB is regulated through the recruitment of coactivators such as CBP (CREB-binding protein), p300, and pCAF (p300/CBP-associated factor) (16, 52, 62) . HPV-16 E6 has been shown to down-regulate NF-iJB activation through its interaction with CBP/p300 (49) . This effect of E6 is independent of its ability to degrade p53 (49) and this interaction between E6 and CBP/p300 results in downregulation of promoters that required NF-KB, such as IL-8, another important chemoattractant of immune cells (28). Additionally, HPV-16 E7 has been shown to bind to pCAF as well as p300 (3, 6, 28 ) and inhibit its co-activator function.
To test whether the repressive effects of E6 and E7 on MIP-3a are occurring through similar mechanisms, we used a mutant of HPV-16 E6 (E6 C66G/C136G) that was shown previously not to bind to CBP/p300 (49) and a mutant of HPV-16 E7 (E7.2) that exhibits less binding to pCAF compared to wild-type HPV-16 E7 (28). In addition to control cells and E6/E7-expressing keratinocytes, cell lines were generated expressing E6 alone (E6/E7stop), E6 C66G/C 136G (E6 C66G/C 136G/E7stop), E7 alone (E6stop/E7), and E7.2 (E6stop/E7.2).
Results following Poly(I)-Poly(C) treatment of two independent cells lines showed statistically significant repression of MIP-3a mRNA in the E6/E7 and E6-expressing keratinocytes compared to control cells, but MIP-3 a mRNA level in the cell line expressing E6 C66G/C 136G was close to the level of control cells ( Figure 6C ). Similar results were observed when using E6/E7, E7, and E7.2-expressing keratinocytes ( Figure 6D ), suggesting that the interaction of HPV-16 E6 and E7 with CBP/p300 and pCAF contributes to the overall repression of MIP-3a production in keratinocytes. Results from this study demonstrate that expression of HPV-16 E6 and E7 in human keratinocytes down-regulates the level of MIP-3a mRNA and protein. The decreased MIP-3a production by E6/E7-expressing keratinocytes reduces the migration of immature Langerhans cell precursors expressing CCR6. Interestingly, the E6/E7 proteins from the low-risk HPV types 6 and 11 are also capable of modulating MIP-3a expression and this may account for the persistence of genital warts in infected individuals. This is a singular instance where the E6 and E7 proteins from low-risk types exhibit a biological behavior that is similar in quality and quantity to that of E6/E7 from high-risk types.
However, E6 and E7 from HPV-16 appear to have an immune-modulatory role that is more broad than the simple effects on MIP-3 a, as indicated by the down-regulation of numerous other cytokines, chemokines, wound healing factors, immune receptors, and adhesion molecules presented in this study ( Table 1 ). Many of the immune factors identified in Table 1 The activation of many immune response genes is mediated by NF-,B, a transcription factor that is a target of bacterial products, viral infections, and pro-inflammatory cytokines such as TNF-a and IL-113, and acts as a mediator in the expression of immune-related genes. Nearly two-thirds of the targets identified as being down-regulated in E6/E7-expressing keratinocytes (Table 1) are target genes of the NF-iB signaling cascade (17, 47) . HPV-16 E6 and E7 have been shown to bind NF-iJB coactivators, p300 and pCAF (3, 6, 28, 49) . This interaction of E6 with p300 and E7 with pCAF resulted in decreased IL-8 promoter activity (28) and is implicated in the present study in the repression of MIP-3a transcription. Since E6 and E7 from both high and low-risk viruses modulated MIP-3a production, the mechanisms may be shared between them. The ability of E6 and E7 of low-risk HPV types to also bind p300 and pCAF (3, 6, 28, 45, 49) suggests that the interaction of E6 and E7 with these coactivators could be the mechanism underlying the repression of MIP-3a observed in HPV-16, HPV-6 and HPV-11 E6/E7-expressing cell lines.
In summary, the results reported here concentrated on MIP-3a, a potent chemoattractant for immature LCs, and showed that E6 and E7 from HPV-16 independently reduced transcription. The resulting decrease in MIP-3a production reduced the overall number of LPLCs migrating in response to this immune chemoattractant. Interestingly, the E6/E7 proteins from low-risk types also exhibited the same reduction in MIP-3a. The ability of E6 and E7 to lessen the production of immune mediators, such as MIP-3a, by infected cells would allow the virus to remain undetected and increase the probability of viral persistence and disease progression. 
